Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21653256 | 0.92 | MAPT (0.34) | TP53MAPTMAPK1MEN1KMT2A | |
| SCHEMBL21653160 | 0.86 | MEN1 (0.35) | TP53MAPTMAPK1MEN1KMT2A | |
| SCHEMBL21653153 | 0.86 | ALDH1A1 (0.36) | TP53MAPTMAPK1MEN1KMT2A | |
| SCHEMBL21653074 | 0.85 | GSK3B (0.38) | MAPTMAPK1MEN1KMT2ARXFP1 | |
| SCHEMBL21652879 | 0.83 | LRRK2 (0.40) | TP53MAPTMAPK1MEN1KMT2A | |
| SCHEMBL21653151 | 0.80 | PDE10A (0.35) | TP53MAPTMAPK1MEN1KMT2A | |
| SCHEMBL21653146 | 0.79 | MET (0.33) | TP53MAPTMAPK1KMT2AHTT | |
| SCHEMBL21653277 | 0.78 | AR (0.35) | MAPTMAPK1MEN1KMT2ARXFP1 | |
| SCHEMBL21653232 | 0.78 | MAPT (0.34) | MAPTMAPK1MEN1KMT2A | |
| SCHEMBL21653164 | 0.77 | MAPT (0.37) | MAPTMAPK1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356174-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3826999-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme Inc (US) | 2021-06-02 | — | — | EP | disclosed |
| CN-112739690-A | Pyridin-2-one compounds as SMARCA2 antagonists | 埃皮兹姆公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356174-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | SMARCC1, SMARCC2, SMARCE1 | TP53 203/4885MAPT 4224/4885MAPK1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.